May 8, 2018
- Activities Report of the Generic Drugs Program (FY 2018) Monthly Performance (updated)
- Pediatric Exclusivity Granted (updated)
- Auromedics Pharma LLC Issues Voluntary Nationwide Recall of Ampicillin and Sulbactam For Injection USP 3 Grams Due to The Presence of Visible Particulate Matter
- Drugs@FDA Data Files (updated)
- FDA Drug Shortages
- Clonazepam Tablets (New - Discontinuation)
- Dextroamphetamine Sulfate Extended-Release Capsules (New - Discontinuation)
- Dextrose 5% Injection Bags (Updated - Currently in Shortage)
- Disulfiram Tablets (New - Discontinuation)
- Etoposide Injection (Updated - Currently in Shortage)
- Heparin Sodium and Sodium Chloride 0.9% Injection (Updated - Currently in Shortage)
- Indomethacin Capsules (New - Discontinuation)
- Lidocaine Hydrochloride (Xylocaine) and Dextrose Injection Solution-Premix Bags (Updated - Currently in Shortage)
- Metronidazole Injection, USP (Updated - Currently in Shortage)
- Morphine Sulfate Extended-Release Tablets (New - Discontinuation)
- Penicillin G Benzathine (Bicillin L-A) Injection (Updated - Resolved)
- Pentoxifylline Extended-Release Tablets (New - Discontinuation)
- Potassium Chloride Injection (Updated - Currently in Shortage)
- Sodium Chloride 0.9% Injection Bags (Updated - Currently in Shortage)
- Sterile Water (Updated - Currently in Shortage)
- Waivers, Exceptions, and Exemptions from the Requirements of Section 582 of the Federal Food, Drug, and Cosmetic Act Guidance for Industry(PDF - 117KB)
.png)
No hay comentarios:
Publicar un comentario